@article {1580494,
	title = {Gene editing technology: Towards precision medicine in inherited retinal diseases},
	journal = {Semin Ophthalmol},
	volume = {36},
	number = {4},
	year = {2021},
	month = {2021 May 19},
	pages = {176-184},
	abstract = {Purpose: To review preclinical and clinical advances in gene therapy, with a focus on gene editing technologies, and application to inherited retinal disease.Methods: A narrative overview of the literature, summarizing the state-of-the-art in clinical gene therapy for inherited retinal disease, as well as the science and application of new gene editing technology.Results: The last three years has seen the first FDA approval of an in vivo gene replacement therapy for a hereditary blinding eye disease and, recently, the first clinical application of an in vivo gene editing technique. Limitations and challenges in this evolving field are highlighted, as well as new technologies developed to address the multitude of molecular mechanisms of disease.Conclusion: Genetic therapy for the treatment of inherited retinal disease is a rapidly expanding area of ophthalmology. New technologies have revolutionized the field of genome engineering and rekindled an interest in precision medicines for these conditions.},
	issn = {1744-5205},
	doi = {10.1080/08820538.2021.1887903},
	author = {Ballios, Brian G and Pierce, Eric A and Huckfeldt, Rachel M}
}
